Table 2.
Pathways of circRNAs degradation.
Degradation pathways | Location | Interacting molecule | Related disease | Reference number |
---|---|---|---|---|
Endonuclease-mediated degradation | Nuclear/cytoplasm |
RNase H1, Template DNA strand / RNase L, PKR |
Systemic lupus erythematosus | 29,33 |
Ago2-mediated degradation | Nuclear | miRNA, Ago2 |
Chronic inflammatory pain |
35–37 |
GW182-mediated degradation | \ | GW182 | \ | 38 |
m6A modification-mediated degradation | Cytoplasm | YTHDF2, HRSP12, RNase-P/MRP | Hepatocellular carcinoma | 40–42 |
Structure-mediated degradation | Cytoplasm | G3BP1, UPF1 | \ | 43 |
TMAO-mediated degradation | Cytoplasm | TMAO | Dysbacteriosis in gut | 45 |
Exosome-mediated degradation | Extracellular space | exosomes/ microvesicles | \ | 48 |